MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 14.03.2026
Novo Nordisk A/S Betriebsaufwand 2011-2026 | NVO
Betriebsaufwand Jährlich Novo Nordisk A/S
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 51.9 B | 10.4 B | 9.88 B | 9.53 B | 9.41 B | 8.7 B | 9.68 B | 9.28 B | 8.39 B | 8.22 B |
Alle Zahlen in DKK-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 51.9 B | 8.22 B | 13.5 B |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M |  USA |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M |  Canada |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
65.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Cabaletta Bio
CABA
|
172 M | $ 2.82 | 1.44 % | $ 283 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Esperion Therapeutics
ESPR
|
343 M | $ 2.85 | 3.26 % | $ 592 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Equillium
EQ
|
23.6 M | $ 2.06 | - | $ 118 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.29 | -3.01 % | $ 329 M | Britain |
 |
Stoke Therapeutics
STOK
|
205 M | $ 33.7 | -0.27 % | $ 2 B | USA |
 |
Atreca
BCEL
|
98.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
854 M | - | - | $ 546 M | USA |
 |
Heron Therapeutics
HRTX
|
281 M | $ 0.83 | 3.62 % | $ 138 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
142 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
120 M | - | - | $ 3.74 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Avid Bioservices
CDMO
|
26 M | - | - | $ 789 M | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Savara
SVRA
|
124 M | $ 5.25 | -0.57 % | $ 1.17 B | USA |
 |
China SXT Pharmaceuticals
SXTC
|
5.04 M | $ 1.32 | -5.2 % | $ 1.88 M | China |
 |
Bellerophon Therapeutics
BLPH
|
22.4 M | - | -74.18 % | $ 955 K | USA |
 |
Kala Pharmaceuticals
KALA
|
41 M | $ 0.2 | -6.67 % | $ 759 K | USA |
 |
Tarsus Pharmaceuticals
TARS
|
69.2 M | $ 67.2 | 0.36 % | $ 2.81 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
668 M | $ 47.55 | 0.98 % | $ 4.28 B |  Schweiz |
 |
Arbutus Biopharma Corporation
ABUS
|
52.2 M | $ 4.45 | -1.77 % | $ 853 M | Canada |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | USA |